VivoSeq
Respiratory

Chronic Obstructive Pulmonary Disease

449

Pipeline Programs↗

67

Active Trials↗

100

Companies Involved↗

Chronic Obstructive Pulmonary Disease is a highly competitive landscape with 449 programs across 100 companies. The most active players are Bambusa Therapeutics, Gilead, Meridigen Biotech Co., Ltd.. 106 therapies are approved with 89 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

92/100

Pipeline Velocity

57/100

Mech. Concentration

10/100

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Bambusa Therapeutics

1 program

Phase 1Gilead logo

Gilead

1 program

Phase 1M

Meridigen Biotech Co., Ltd.

1 program

Phase 1N

Nobilis Therapeutics Inc.

1 program

Phase 1J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1K

Kang Stem Biotech Co., Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical61

Curcumin

Merck & Co.

Aclidinium Bromide

AstraZeneca

Tiotropium Bromide

Boehringer Ingelheim

Formoterol Fumarate

AstraZeneca

Beclomethasone

Chiesi Farmaceutici S.p.A.

Phase 144

Canakinumab

Novartis

Quercetin

Mayo Clinic

Xenon

Nobilis Therapeutics Inc.

Resveratrol

National Cancer Institute (NCI)

Cyclosporine

Novartis

Phase 2149

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Megestrol Acetate

Bristol-Myers Squibb

Lebrikizumab

Eli Lilly

Ulinastatin

Techpool Bio-Pharma Co., Ltd.

Phase 389

Infliximab

Organon and Co

Montelukast Sodium

AstraZeneca

Metoprolol Succinate

AstraZeneca

Mepolizumab

Glaxo Dba Glaxosmithkline

Benralizumab

AstraZeneca

Approved106

Dexamethasone

Aspen Global Incorporated

Salmeterol

Glaxo Dba Glaxosmithkline

Clopidogrel

Sanofi

Indacaterol

Novartis

Furosemide

Validus Pharmaceuticals

Analysis

Modality Breakdown

96%

Small molecule

510 of 534 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody132%Cell therapy61%Peptide3<1%Vaccine2<1%

Small molecule leads; the ring shows all 534 classified programs, each share of the total. Modality classified for 99% of 558 pipeline programs.

Analysis

Trial Status

775

clinical trials

Completed578 · 75%
Terminated62 · 8%
Unknown status48 · 6%
Recruiting35 · 5%
Withdrawn19 · 2%
Not yet recruiting19 · 2%
Other14 · 2%

Clinical Trials

Trial Activity

775 trials

Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease
Recruiting·—·N/A·NCT05495698·300 enrolled
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
Recruiting·GSK logoGSK·Phase 3·NCT06959095·981 enrolled
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Recruiting·BBambusa Therapeutics·Phase 1·NCT07288554·68 enrolled
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Recruiting·Sanofi logoSanofi·Phase 3·NCT07190209·942 enrolled
Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease
Recruiting·HHanlim Pharm. Co., Ltd.·Phase 2·NCT06434792·96 enrolled
Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial
Recruiting·—·N/A·NCT07022704·35 enrolled
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Recruiting·Sanofi logoSanofi·Phase 4·NCT07053423·218 enrolled
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT07082738·1,160 enrolled
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 3·NCT07039669·594 enrolled
Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease
Recruiting·—·Phase 4·NCT05703919·1,888 enrolled
Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05844462·200 enrolled
A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06748079·72 enrolled
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Recruiting·Sanofi logoSanofi·Phase 3·NCT07190222·942 enrolled
Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy
Recruiting·RRegend Therapeutics·Phase 1·NCT07355868·12 enrolled
Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).
Recruiting·SSMSbiotech·Phase 1·NCT06986070·18 enrolled
Page 1 of 52

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)